EXCALIBUR feasibility trial of Shufeng Jiedu for acute exacerbations of COPD

Phase 3, randomised, double-blind trial in chronic obstructive pulmonary disease (COPD) comparing Shufeng Jiedu plus usual care with Placebo plus usual care (2 arms). Primary endpoints: Number and proportion of patients on the COPD register who present with acute exacerbation of COPD, Proportion of patients presenting with acute exacerbation of COPD who are eligible and ineligible and 11 more. Started Jul 2021; status: completed.